AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Intra-Cellular Therapies ... (ITCI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

127.97

0.15 (0.12%)

At close: Feb 18, 2025, 3:59 PM

127.58

-0.30%

After-hours: Feb 18, 2025, 05:20 PM EST

undefined% (undefined)

Bid	127.58
Market Cap	13.60B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.87
PE Ratio (ttm)	-147.09
Forward PE	n/a
Analyst	Hold

Ask	131
Volume	1,110,152
Avg. Volume (20D)	2,507,196
Open	127.91
Previous Close	127.82
Day's Range	127.91 - 128.13
52-Week Range	62.78 - 128.19
Beta	undefined

About ITCI

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as ...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jan 7, 2014

Employees 610

Stock Exchange NASDAQ

Ticker Symbol ITCI

Website https://www.intracellulartherapies.com

Full Company Profile

Analyst Forecast

According to 13 analyst ratings, the average rating for ITCI stock is "Hold." The 12-month stock price forecast is $100, which is a decrease of -21.86% from the latest price.

Buy 53.85%

Hold 46.15%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Intra-Cellular Therapies Inc. is scheduled to release its earnings on Mar 4, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+34.07%

Intra-Cellular Therapies shares are trading higher... Unlock content with Pro Subscription

3 months ago

+11.36%

Intra-Cellular Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 net product sales guidance. Also, Needham reiterated a Buy rating on the stock.

News

4 weeks ago · cnbc.com

Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.

1 month ago · zacks.com

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.

1 month ago · zacks.com

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

Intra-Cellular (ITCI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down ...

1 month ago · businesswire.com

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Intra-Cellular T...

1 month ago · businesswire.com

Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Joh...

1 month ago · https://thefly.com

BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal

Intra-Cellular +32.49 (+34.25%) Johnson & Johnson +2.22 (+1.56%)

1 month ago · zacks.com

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.

1 month ago · reuters.com

Drugmakers rush to sign deals on first day of industry conference

Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's top conference in San Francisco.

1 month ago · https://thefly.com

Intra-Cellular just downgraded at Morgan Stanley, here's why

Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)

1 month ago · investopedia.com

Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion.

Load More News